Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00992095 · ClinicalTrials.gov registry record · NA
Bioequivalency Study of Buprenorphine Hydrochloride 8 mg Tablet Under Fasted Conditions
A NA study of Opioid-Related Disorders, sponsored by Roxane Laboratories.
- Completed
- Registry status
- NA
- Development phase
- 48
- Enrollment target
- 1
- Study location
NCT00992095 is a NA study of Opioid-Related Disorders that has completed, run by Roxane Laboratories. The registered enrollment target is 48 participants, below the 346-participant average among 47 other Opioid-Related Disorders trials with a reported enrollment target (86% lower). The trial reports 1 study location across 1 state.
The verdict
NCT00992095, a NA study of Opioid-Related Disorders, has completed, sponsored by Roxane Laboratories.
- COMPLETED
- Registry status
- NA
- Development phase
- 48 participants
- Enrollment target
- 1
- Study location
Study Summary
The objective of this study was to prove the bioequivalence of Buprenorphine HCl 8 mg tablet under fasted conditions.
Conditions Studied
Interventions
- DRUG buprenorphine hydrochloride
Study Locations (1)
Texas
- CEDRA Clinical Research - Austin
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 48 participants |
| Start Date | 2006-08 |
| Est. Completion | 2006-09 |
| Phase | NA |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00992095
The ClinicalTrials.gov registry entry for NCT00992095 describes a study currently listed as completed, categorized as NA. The registered enrollment target is 48 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 346-participant average among 47 other Opioid-Related Disorders trials with a reported enrollment target (86% lower). The listed sponsor is Roxane Laboratories, which has 93 total studies on file at ClinicalTrials.gov.
The record links to 1 condition, with Opioid-Related Disorders appearing as the primary indexed condition, and to 1 intervention - of which buprenorphine hydrochloride is the first listed.
NCT00992095 reports 1 study location spanning 1 distinct geographic area - top geographies include Texas.
Frequently Asked Questions
What is clinical trial NCT00992095 about?
NCT00992095 is a clinical study titled "Bioequivalency Study of Buprenorphine Hydrochloride 8 mg Tablet Under Fasted Conditions". The objective of this study was to prove the bioequivalence of Buprenorphine HCl 8 mg tablet under fasted conditions.
What is the current status of trial NCT00992095?
This trial is currently completed. It is a NA study. The enrollment target is 48 participants. The study started on 2006-08. Estimated completion is 2006-09.
What conditions does trial NCT00992095 study?
This clinical trial studies the following conditions: Opioid-Related Disorders.
What interventions are being tested in trial NCT00992095?
The interventions under investigation include: buprenorphine hydrochloride (DRUG).
Who is sponsoring clinical trial NCT00992095?
This trial is sponsored by Roxane Laboratories, which has 93 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT00992095 being conducted?
This trial has 1 study location across Texas. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Opioid-Related Disorders
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
Developing and Evaluating a Machine-Learning Opioid Overdose Prediction & Risk-Stratification Tool in Primary Care
RECRUITING · NA
-
Developing a Smartphone Application to Support Veteran Opioid Use Disorder Treatment
RECRUITING · NA
-
OUD Smartphone Services
ACTIVE NOT RECRUITING · NA
-
Developing a Tailored Stigma Reduction Intervention to Increase Buprenorphine Prescribing
ACTIVE NOT RECRUITING · NA
-
Healthy Opioid Prescription Engagement
ACTIVE NOT RECRUITING · NA
-
Kentucky Outreach Service Kiosk (KyOSK): Reducing HIV, HCV, and Overdose Risk
ACTIVE NOT RECRUITING · NA
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.